Nanoform, an innovative drug particle engineering and nanotechnology company that provides novel API particle-size reduction services, is continuing its strategic growth through a significant €7 million investment.
The money will be used to further develop its best-in-class nanonisation capabilities by funding a new GMP-compliant facility and facilitating a tactical global commercialisation plan.
Attrition in the drug development pipeline is a critical challenge facing pharmaceutical companies. More than 90% of drug development projects fail to successfully complete all of the phases required to make a novel therapeutic available to patients. Nanoform’s multi-patented Controlled Expansion of Supercritical Solutions (CESS) uses its groundbreaking API nanonisation technology to enable its partners to significantly decrease attrition rates across all stages of the drug development pipeline.
This novel particle-size reduction technique can transform the overall therapeutic performance of an API through a substantially improved dissolution rate, helping the global pharma industry to double its output of new drugs.
Supercritical fluid nanonisation is an innovative drug particle engineering technique where the recrystallisation of the API is controlled in supercritical carbon dioxide through thermodynamics.
CESS is unique as it is more controlled than any of the conventional supercritical platforms currently available. All APIs refined by Nanoform have a smaller and more homogeneous particle size than the bulk API, with the ability of the manufacturing process to be scaled up for commercial production. The capital gained from this latest funding will allow Nanoform to build upon its previous success of nanonising more than 20 APIs.
Nanoform will extend its offerings to nanonising clinical stage APIs through building a state-of-the art GMP-compliant facility, which is scheduled to open next year. The strategic investment will also allow Nanoform to begin its international commercialisation strategy to further broaden its services and capabilities.
This innovative technology allows Nanoform to work synergistically with its clients, giving drugs that have previously failed in the pipeline a second chance. Nanoform can also shield API owners from generic competition through prolonging patents by significantly improving and differentiating the physical properties of a chosen drug.
Edward Hæggström, CEO of Nanoform, said: “We are delighted to have secured this opportunity with Vator Securities, this significant investment will help to advance drug development for global pharma. The investment will enable our best-in-class nanonization services to undergo strategic growth to meet with the growing demand in industry for APIs exhibiting an enhanced dissolution rate and bioavailability.”